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Abstract
Background: Pharmaceutical companies spent $57.5 billion on pharmaceutical promotion in the United States in 2004. The
industry claims that promotion provides scientific and educational information to physicians. While some evidence indicates
that promotion may adversely influence prescribing, physicians hold a wide range of views about pharmaceutical
promotion. The objective of this review is to examine the relationship between exposure to information from
pharmaceutical companies and the quality, quantity, and cost of physicians’ prescribing.
Methods and Findings: We searched for studies of physicians with prescribing rights who were exposed to information from
pharmaceutical companies (promotional or otherwise). Exposures included pharmaceutical sales representative visits, journal
advertisements, attendanceatpharmaceuticalsponsored meetings, mailed information, prescribingsoftware,and participation
in sponsored clinical trials. The outcomes measured were quality, quantity, and cost of physicians’ prescribing. We searched
Medline (1966 to February 2008), International Pharmaceutical Abstracts (1970 to February 2008), Embase (1997 to February
2008), Current Contents (2001 to 2008), and Central(TheCochrane Library Issue 3,2007) using the search terms developed with
an expert librarian. Additionally, we reviewed reference lists and contacted experts and pharmaceutical companies for
information. Randomized and observational studies evaluating information from pharmaceutical companies and measures of
physicians’ prescribing were independently appraised for methodological quality by two authors. Studies were excluded where
insufficient study information precluded appraisal. The full text of 255 articles was retrieved from electronic databases (7,185
studies) and other sources (138 studies). Articles were then excluded because they did not fulfil inclusion criteria (179) or quality
appraisal criteria (18), leaving 58 included studies with 87 distinct analyses. Data were extracted independently by two authors
and a narrative synthesis performed following the MOOSE guidelines. Of the set of studies examining prescribing quality
outcomes, five found associations between exposure to pharmaceutical company information and lower quality prescribing,
four did not detect an association, and one found associations with lower and higher quality prescribing. 38 included studies
found associations between exposure and higher frequency of prescribing and 13 did not detect an association. Five included
studies found evidence for association with higher costs, four found no association, and one found an association with lower
costs. The narrative synthesis finding of variable results was supported by a meta-analysis of studies of prescribing frequency
that found significant heterogeneity. The observational nature of most included studies is the main limitation of this review.
Conclusions: With rare exceptions, studies of exposure to information provided directly by pharmaceutical companies have
found associations with higher prescribing frequency, higher costs, or lower prescribing quality or have not found
significant associations. We did not find evidence of net improvements in prescribing, but the available literature does not
exclude the possibility that prescribing may sometimes be improved. Still, we recommend that practitioners follow the
precautionary principle and thus avoid exposure to information from pharmaceutical companies.
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Pharmaceutical companies in the United States spent about
US$57.5 billion, or 24.4% of their revenue, on promotion in 2004
[1]. One estimate of total promotional expenditure in France for
2004 is J2,908 million (12.2% of revenue). However, another
estimate is that pharmaceutical detailing cost J3,300 million and
accounted for 75% of the overall cost of promotion in that year
making promotion 17.3% of revenue [2]. Expenditure on
promotion is aimed at maximizing returns for the corporation
and shareholders [3]. The industry claims that promotion also
provides scientific and educational information to healthcare
professionals: ‘‘Appropriate marketing of medicines ensures that
patients have access to the products they need and that the
products are used correctly for maximum patient benefit. Our
relationships with healthcare professionals are critical to achieving
these goals because they enable us to – inform healthcare
professionals about the benefits and risks of our products to help
advance appropriate patient use, provide scientific and education-
al information, support medical research and education’’ [4].
There is a wide range of views amongst health professionals
about pharmaceutical promotion. Qualitative studies suggest that
many perceive pharmaceutical promotion to be a useful and
convenient source of information [5–7]. Some doctors deny that
they are influenced by pharmaceutical company promotion or
claim that it influences others but not themselves [8–10].
Nonetheless, many of these physicians are willing to give
significant amounts of time to engaging in promotional activities
[11]. By contrast, several professional organisations have called for
more control of promotional activities [12,13] because of evidence
that promotion may be misleading [14–17].
The evidence base illuminating these conflicting views is
growing. In 2000, Wazana identified eight studies linking
pharmaceutical promotion to increased prescribing, ‘‘nonrational
prescribing,’’ and increased prescribing costs [18]. A 2005 review
concluded that promotion influences the prescribing by physicians
in training [19], and a second review in the same year concluded
that sales representatives influence prescribing [20].
Those previous reviews are now out of date, narrowly focused,
or only partially assessed the relationship between information
(promotional or otherwise) from pharmaceutical companies and
prescribing costs and quality. The objective of this review is to
examine the relationship between exposure to information directly
provided by pharmaceutical companies and the quality, quantity,
and cost of physicians’ prescribing.
Methods
Criteria for Including Studies
Randomized controlled trials, time series analyses, before–after
studies, cohort studies, case-control studies, ecological studies, and
cross-sectional studies were eligible for inclusion. Studies were
included if they had both a measure of exposure to any type of
information directly provided by pharmaceutical companies and a
measure of physicians’ prescribing. We excluded studies that
looked at the indirect provision of information, for example,
through continuing medical education courses that were funded by
unrestricted grants from pharmaceutical companies. Case series,
case reports, abstracts, news items, and short reports were
excluded.
Exposure to information directly provided by pharmaceutical
companies was defined as including pharmaceutical sales repre-
sentative visits, advertisements in journals or prescribing software,
presentations from pharmaceutical companies to groups, meetings
sponsored by pharmaceutical companies, mailed information
including advertisements, and participation in sponsored clinical
trials. We did not include studies of other forms of promotion such
as gifts or samples or studies of indirect forms of information
provision such as sponsored education.
The outcome measures were the quality, frequency, and costs of
prescribing.
Search Methods for Identification of Studies
We searched Medline (1966 to February 2008), International
Pharmaceutical Abstracts (1970 to February 2008), Embase (1997
to February 2008), Current Contents (2001 to 2008), and Central
(The Cochrane Library Issue 3, 2007). The search strategy below
was devised for Medline by an expert librarian at the University of
Queensland and adapted for the other databases: (exp Drug
Industry OR exp Advertising OR exp Gift Giving OR exp
‘‘Conflict of Interest’’) AND (exp Prescriptions, Drug/OR
(prescribing or prescription$).mp.))
We looked for additional articles in the references of each
retrieved article including review articles in an iterative, exhaustive
process. Efforts to find additional studies included placement of
messages on email drug discussion groups, contacting experts in
the field, and asking Australian subsidiaries of international
pharmaceutical companies for information. All languages were
considered.
Selection of Studies
The title and abstract, if available, of all articles detected by the
database searches were reviewed by two authors. Articles that
possibly met the inclusion criteria were retrieved and subjected to
a formal inclusion process independently by two different authors.
Differences of opinion were resolved by consensus and if necessary
a third author was involved.
Quality Appraisal
Articles meeting inclusion criteria were appraised for method-
ological quality independently by two authors. Randomized
studies were assessed for adequacy of randomization method,
allocation concealment, blinding, follow-up, and use of intention
to treat analyses [21]. Controlled cohort and case-control studies
were assessed using the Newcastle-Ottawa scales [22]. For other
nonrandomized studies, quality appraisal included assessment of
sources of bias, for example presence of a control group, selection
methods, control of confounding, response rate (.80%), and use
of appropriate statistical tests [23]. Studies were only excluded
from the review if two authors found there was insufficient
information to appraise their quality. Disagreements were resolved
by discussion with a third author.
Data Extraction
For included studies, two authors independently extracted data
on study site, dates of data collection or publication, types of
participants (primary care providers, specialists, and residents),
study medication(s), exposure to information from pharmaceutical
companies, and prescribing outcomes.
Reporting of Results
For quality of prescribing we accepted the original authors’
definitions of what constituted more (or less) appropriate
prescribing.
We divided studies into two groups on the basis of whether the
information was delivered with or without conventional promo-
tional techniques. This distinction was made because information
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produce different effects on prescribing.
Conventional promotional techniques were defined as adver-
tisements (in journals and software), representatives’ visits,
attendance at pharmaceutical sponsored meetings, and mailed
information from pharmaceutical companies. In addition, we
included in this group studies looking at total promotional
investment/summated scores of commercial information use/
general use of commercial sources. The other group of studies
included warning letters, participation in company sponsored
trials, and representatives’ visits for nonpromotional purposes.
A narrative synthesis of results was undertaken following the
MOOSE guidelines and meta-analysis performed where appro-
priate data were available (Text S1) [24]. The unit of analysis was
defined as the combination of exposure to a type of information
from a pharmaceutical company (for example pharmaceutical
sales representative visits or journal advertisements) and a type of
prescribing outcome (quality, frequency, and cost of prescribing).
Thus studies were treated as a single unit of analysis if they
measured the same type of exposure and the same type of outcome
regardless of the number of drugs covered in each study. We
classified each analysis as positive or negative rather than no
association detected if the p value was less than 5% (p,0.05)
regardless of the magnitude of the effect.
We reported standardized effect measures (Pearson correlation
coefficients, odds ratios [ORs], or beta coefficients) where study
reports provided them or the data needed to calculate them. For
econometric studies, we also reported t statistics where they were
reported or it was possible to calculate them.
Meta-analysis was not appropriate for the outcomes of quality of
prescribing and cost of prescribing because in both cases the
studies examined different exposures or outcome measures and/or
lacked control groups. We undertook a meta-analysis for one
component—studies of frequency of prescribing with identifiable
control groups where the information exposure was delivered with
conventional promotional techniques. We used ORs for change in
prescribing frequency as the outcome measure. Where studies had
suitable designs for inclusion in the meta-analysis but ORs and
standard errors were not published we contacted corresponding
authors. Out of ten studies [25–34], we received four replies of
which three provided the information we required [29–31].
Heterogeneity was assessed using the tau squared test with a
sensitivity analysis to investigate likely sources of heterogeneity.
Factors identified a priori as possible explanations for heteroge-
neity were study design, study quality indicators, year of
publication, type of exposure to pharmaceutical company
information (active versus passive), and physician characteristics
(level of experience and also primary care provider versus
specialist). We defined active exposure as information presented
to physicians at meetings or during pharmaceutical sales
representatives’ visits. We defined passive exposure as journal
advertisements, mailed information, advertisements on clinical
software, and participation in sponsored clinical trials. Studies
reporting more than one unit of analysis were subjected to
sensitivity analysis. Meta-analysis was performed using RevMan
(version 5.0.24) with further analysis conducted using Stata version
10.0 (Stata Corporation).
Results
Search Results
Our search found 7,185 studies from electronic databases and
138 studies were retrieved from reference lists, experts in the field
and email lists. The full text of 255 articles was retrieved. 18
studies were excluded, all because inadequate reporting precluded
quality assessment. Quality appraisal results for included studies
are presented in Tables 1–5. Following application of inclusion/
exclusion criteria and quality appraisal, 58 studies were included in
the review (52 published in journals [25–33,35–77], three reports
[78–80], one dissertation [34], one conference presentation [81],
and one conference poster [82] (Figure 1). Of these 58, 29 studies
came from database searches [25–31,33,35–38,41,44,55,56,59–
62,66–68,70–72,74,76,77], 22 studies came from reference lists
[32,39,40,46–54,58,63–65,69,73,75,78,79], five studies came from
experts in the field [34,43,57,81,82], and two from email lists
[45,80]. These 58 studies included 87 units of analysis.
Pharmaceutical companies provided 62 citations; two of these
met our inclusion criteria and had already been identified through
Medline searches [27,35]. Five of the studies located through the
e-mail lists and experts were not indexed in the databases we
searched [34,43,80–82]. For one study [78], additional data were
obtained from the authors [83].
General Characteristics of Studies
The most common study design was cross-sectional (24/58
studies, 41%). There were also two cluster randomized controlled
trials, one controlled-cohort study, two case-control studies, 24
time-series analyses, and five before–after studies. Over half (55%)
of the studies were conducted in the United States. Characteristics
of included studies are outlined in Table 6.
Pharmaceutical Company Information and Prescribing
Quality
Prescribing quality was measured by ten studies with 14 units of
analysis [37,39,58,59,61,64,74,77,81,82] (Table 7). Quality was
assessed in four distinct ways: quality scoring of prescribing
decisions, guideline adherence, prescribing appropriateness of an
individual drug class, and prescribing range. Three studies used
quality scores calculated by coding physicians’ drug choices in
responses to clinical vignettes [74,81,82]. One of these used an
expert panel to derive a quality index (1–100) judging primary
care providers’ prescribing in response to both their actual
prescribing and clinical vignettes [81]. In the latter study learning
about the drug first from pharmaceutical sales representatives was
associated with lower quality of actual prescribing but the number
of pharmaceutical sales representatives’ visits was not. There was
no significant association between primary care providers seeing
more pharmaceutical sales representatives or first learning about
the drug from pharmaceutical sales representatives and lower
quality responses to case vignettes [81]. Another study combined
scales examining indication, effectiveness, safety, dosage, duration,
and polypharmacy to produce a seven-point scale measuring
rationality of prescribing [74]. Primary care providers’ self-
reported reliance on pharmaceutical companies for information
was associated with lower quality scores [74]. A third study used a
quality score for a hypertension scenario where thiazides were
considered very appropriate and all other drug groups were
considered very inappropriate [82]. Self-reported rates of
attendance at pharmaceutical company-sponsored meetings were
associated with slightly lower quality scores, but self-reported rates
of pharmaceutical sales representative visits had no significant
association [82].
Residents attending a sponsored meeting were more likely than
nonattending residents at the same hospital to prescribe the
sponsoring company’s medication, both when it was appropriate
according to the authors and when it was not [39].
Primary care providers who saw more pharmaceutical sales
representatives and those who used the pharmaceutical industry in
Pharma Information and Prescribing
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drugs [61]. The authors suggested that this was a sign of lower
prescribing quality in the context of recommendations that
primary care providers use a limited list of drugs they know well
[61].
Two studies measured guideline adherence. One found less
adherence by primary care providers who received more frequent
visits from pharmaceutical sales representatives [64], while the
other found no change in adherence by primary care providers
participating in a clinical trial sponsored by a pharmaceutical
company [37].
One study of warnings conveyed by pharmaceutical sales
representatives and mailed information [58], one of mailed
warnings alone [59], and one of representatives’ visits and
advertisements [77] found that there was no alteration in overall
rates of prescriptions judged to be inappropriate.
Pharmaceutical Company Information and Prescribing
Frequency
51 studies [25–54,56–60,62,63,65,67–70,72,73,75–81] mea-
sured prescribing frequency as market share, intention to
prescribe, prescription sales, formulary requests, as well as number
of prescriptions (63 units of analysis) (Table 8). Below we report
separately the results of studies of information delivered with
versus without conventional promotion. Within both groups there
was one unit of analysis per study.
Conventional Promotional Techniques
Pharmaceutical sales representative visits. Of the 29
studies of pharmaceutical sales representative visits, 17 found only
an association with increased prescribing of the promoted drug
[26,32,33,38,40,43–50,63,67,78,79]. None found less frequent
prescribing. Of the remaining 11, six studies had mixed results:
finding a significant association with more frequent prescribing for
some measures but no significant association for others
[27,42,62,69,73,81]. Five did not detect any significant
relationship [31,52,68,72,77]. One study did not use statistical
tests for associations. It found that during the time that spending
by pharmaceutical companies on promotion of a medication
dropped to zero, there was also a significant drop in prescribing of
that medication. However most of the decreases in promotion and
prescribing occurred after the publication of evidence of problems
with that medication [56].
Nine of these studies with either positive or mixed results
provided insights into features of pharmaceutical sales represen-
tative visits that modified the impact of these visits on prescribing
[40,46,49,62,67,69,73,78]. An association with more frequent
prescribing was more likely when pharmaceutical sales represen-
tatives visited groups of physicians, when physicians had lower
baseline prescribing of the promoted drug [62], and when
physicians had larger prescribing volumes overall [67]. Longer
pharmaceutical sales representative visits to physicians and
residents were also more likely to be associated with increased
prescribing [69,73]. More frequent pharmaceutical sales repre-
sentative visits were associated with diminishing returns
[46,50,69].
In addition to increasing the promoted drug’s market share,
pharmaceutical sales representative visits were associated with a
decrease in the market share of competitor products [78].
Pharmaceutical sales representative visits were more likely to be
associated with more frequent prescriptions for drugs judged more
effective and also for drugs with more side effects [40]. However
the authors of that study did not attempt to measure whether
higher levels of use represented a change in prescribing quality.
Another study found that pharmaceutical sales representative visits
were associated with a greater increase in market share for new
entrants into a therapeutic field than was positive scientific
information [49].
Journal advertisements. Four out of the eight studies
measuring the effects of journal advertisements presented data
but did not include statistical tests [25,34,70,80]. One of these
noted use of a medication class increased after pharmaceutical
advertising commenced in a country where the medication class
was previously available but was not promoted [25]. One study
visually compared graphs of the monthly number of
advertisements and prescriptions for a group of nine drugs and
found no clear relationship between the extent of the advertising of
Table 1. Quality appraisal of included studies: randomised controlled trials.
Randomised Controlled
Study (First Author Name) Satisfactory Randomization
Allocation
Concealment Blinding
Adequate
Follow-up
Appropriate
Statistical Measures
Freemantle [35] Appropriate cluster randomization No No Yes Yes
Dolovich [36]
a Appropriate cluster randomization No No Yes Yes
aReceived research funding from a pharmaceutical company.
doi:10.1371/journal.pmed.1000352.t001
Table 2. Quality appraisal of included studies: controlled cohort and case-control studies.
Study Type
Study (First Author
Name)
Prospective
Design
Comparability of
Cases and Controls
Selection Bias
Minimized
Response
Rate .80%
Confounders
Controlled
Appropriate
Statistical
Measures
Adequate
Follow-Up
Controlled
Cohort
Andersen [37]
a No Yes Yes Yes Yes Yes Yes
Case-Control Spingarn [39] No Yes No Yes (100%) Yes Yes Yes
Chren [38] No Yes Yes Yes (88%) Yes Yes Yes
aReceived research funding from a pharmaceutical company.
doi:10.1371/journal.pmed.1000352.t002
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[70]. One study found that the market share of a medication was
higher amongst physicians who recognised the advertisement for
that medication compared to those who did not [80]. The last
study observed decreased prescribing of two drug classes at the
same time that advertising decreased [34].
Of the four studies that included statistical tests, one found
that journal advertisements have a more pronounced effect on
market share for the advertised drug than does positive
scientific information published in medical journals [49]. A
cross-sectional study found contradictory results. Self-reported
infrequent use of journal advertisements by physicians to learn
about new medications was not associated with frequency of
prescribing. However, infrequent use of journal advertisements
was associated with less chloramphenicol prescribing [77].
One cross-sectional study found that physicians who recalled
advertisements became prescribers of the advertised products
in consistently larger proportions than those who did not recall
advertisements [75]. Another study found that 9% of high
prescribers of new drugs cited advertisements as an influence
on their prescribing compared to 0% for low prescribers;
however, this was not a statistically significant association
[67].
Attendance at pharmaceutical company-sponsored meet-
ings. There were eight studies of pharmaceutical company-
sponsored meetings. Five found positive associations with
prescribing frequency [28,31,43,60,65]. Three studies did not
detect a significant association [33,39,40].
Table 3. Quality appraisal of included studies: time-series analyses.
Time-Series
Analysis
Study (First
Author Name)
Prospective
Design
Control
Group
Confounders
Controlled
Selection Bias
Minimized
Appropriate
Statistical Measures
Econometric Ching [78] No No Yes Yes Yes
Venkataraman [40] No No Yes Yes Yes
Windmeijer [41] No No Yes Yes Yes
Chintagunta [42] No No Yes Yes Yes
Narayanan [43] No No Yes Yes Yes
Donohue [44] No No Yes Yes Yes
Mizik [45] No No Yes Yes Yes
Manchanda [46] No No Yes Yes Yes
Manchanda and
Chintagunta [47]
No No Yes Yes Yes
Berndt [48] No No Yes Yes Yes
Rosenthal [79] No No Yes No Yes
Azoulay [49] No No Yes Yes Yes
Rizzo [50] No No Yes No Yes
Hurwitz [51] No No Yes Yes Yes
Mackowiak [52] No No No Yes Yes
Leffler [53] No No Yes Yes Yes
Telser [54] No No Yes Yes Yes
Other Spurling [55] Yes No No No Yes
Stafford [56] Yes No No Yes No
Charbit [34] No No No Yes No
Auvray [57] No No No No No
Cleary [26] Yes Yes Yes No Yes
Soumerai [58] No Yes No Yes No
doi:10.1371/journal.pmed.1000352.t003
Table 4. Quality appraisal of included studies: before–after studies.
Before–After Study (First
Author Name)
Prospective
Design
Control
Group
Response
Rate .80%
Confounders
Controlled
Selection Bias
Minimized
Hemminki [25] No Yes No (68%) No Yes
Schwartz [27] No Yes Unsure No Unsure
Kazmierczak [59] No No NA No Yes
Orlowski [28] No No Yes (100%) Yes No
Bowman [60] Yes No No (43%–77%) No No
doi:10.1371/journal.pmed.1000352.t004
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panies. One of the three studies of mailed promotional ma-
terial found an association with increased prescribing [76]. The
others found no association [33,67].
Advertising in clinical software. A single study examined
the effect of advertising in clinical practice software and found no
association with prescribing frequency for six medications and less
prescribing of one medication [29]. The overall result was no
association between advertising and prescribing frequency.
Total promotional investment. Eight studies combined the
outcome measures for various exposures to pharmaceutical
company information or measured overall promotional invest-
ment, a proxy for the amount of exposure to information from
pharmaceutical companies. Three studies found that total pro-
motional investment was positively associated with prescribing
frequency [30,33,51]. Two studies found both positive results and
no association [53,54]. One study did not detect an association
[52].
Meta-analysis of promotional information and prescrib-
ing frequency. We pooled results from a total of seven studies
using a random effects model to examine whether exposure to
promotion was associated with prescribing of the promoted
medication. The seven study results included in the meta-
analysis showed significant heterogeneity (I
2=91% [95%
confidence interval (CI) 84%–95%], tau
2=0.35), and therefore
we have presented the forest plot without the pooled outcome
(Figure 2) [29,30,31,38,39,63,75]. Using sensitivity analysis we
found that study design, quality factors, year of publication, and
type of physician did not explain this heterogeneity. One study
provided two units of analysis with outcomes amenable to meta-
analysis: a significant association for attendance at sponsored
meetings and a nonsignificant result for pharmaceutical sales
representative (PSR) visits [31]. We included only that
nonsignificant result in the forest plot (Figure 2). When meta-
analysis was conducted using the significantly positive result for
attendance at a pharmaceutical company-sponsored meeting, the
summary result and level of heterogeneity did not differ greatly.
The largest difference detected was between exposure to active
promotional information (OR 2.34, 95% CI 1.50–3.65),
(I
2=59%, 95% CI 0%–86%, tau squared=0.11) [31,38,39,63]
and passive promotional information (OR 1.24, 95% CI 0.72–
2.15) (I
2=89.5%, tau squared=0.14) [29,75].
Information Delivered Without Conventional Promotion
Techniques
Five studies looked for associations between information
delivered without conventional promotion techniques and the
frequency of physicians’ prescribing [35,36,37,58,59]. One
randomized controlled trial partnered a local health authority
Table 5. Quality appraisal of included studies: cross-sectional studies (no control group).
Cross-Sectional Study
(First Author Name)
Prospective
Design
Response
Rate .80%
Confounders
Controlled
Selection Bias
Minimized
Appropriate
Statistical Measures
Henderson [29]
a No Yes Yes Yes Yes
Greving [30] No Yes (96%) Yes Yes Yes
Kreyenbuhl [31] Yes No (58%) No Yes Yes
de Bakker [61] No Unsure Yes Yes Yes
Steinman [62] No Yes Yes No Yes
Canli [32] Yes No (79%) No Yes Yes
Verdoux [63] Yes No (24%) Yes No Yes
Muijrers [64] Yes No (71%) Yes Yes Yes
Huang [65] No NA No No Yes
Watkins [66] Yes No (64%) Yes Yes Yes
Prosser [67] Yes No (73%) No Yes No
Caamano [68] Yes No (75%) Yes Yes Yes
Gonul [69] Yes NA Yes Unsure Yes
Mansfield [82] Yes No (6%) No No Yes
Jones [70] Yes NA No No No
Caudill [71] Yes No (28%) Yes Yes Yes
Berings [72] Yes No (28%) Yes No Yes
Lurie [73] Yes No (75–78%) Yes Yes Yes
Health Care Communications
1989
a [80]
No Unsure No No No
Peay [33] No No (52%–70%) Yes Yes Yes
Blondeel [81] Yes No (30%) Yes Yes Yes
Haayer [74] Yes Yes (90%) Yes No Yes
Walton [75] Yes Unsure No Yes Yes
Dajda [76] No NA No Yes Yes
Becker [77] Yes Yes (84%) Yes Yes Yes
aReceived research funding from a pharmaceutical company.
doi:10.1371/journal.pmed.1000352.t005
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expensive drug [35], and the other randomized controlled trial
aimed to promote rational prescribing through evidence-based
detailing by a pharmaceutical company in partnership with an
academic institution [36]. Neither found an association with
physicians’ prescribing. A single controlled-cohort study of a
pharmaceutical company-funded randomized controlled trial found
that physicians’ participation in recruiting subjects was associated
with an increase in the number of prescriptions of the sponsoring
company’s drug [37]. One time-series analysis found no change in
the rate of decline in the prescribing of a medication when the main
manufacturer was required by a regulatory agency to deliver an
educational program warning about problems with the drug via
mailed information and pharmaceutical sales representative visits
[58]. A cross-sectional study found no change in prescription rates
following warning letters regarding drug side effects [59].
Pharmaceutical Company Information and Prescribing
Costs
Eight studies (Table 9) [35,41,50,55,66,68,69,71] measured
prescribing costs as costs per physician, price elasticity, and
changes in generic prescribing (ten units of analysis). In the United
States, one econometric time-series analysis found that pharma-
ceutical sales representative visits were associated with increased
price sensitivity among physicians prescribing in one therapeutic
class [69], and another found the opposite effect for hypertension
[50]. A third, more recent, econometric study found that
promotional outlay (the total for pharmaceutical sales represen-
Figure 1. Study flow diagram.
doi:10.1371/journal.pmed.1000352.g001
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Study Design
Study (First
Author Name)
Study Site,
Year Participants (n) Medication Intervention/Exposure Outcome Measure(s)
RCT Freemantle [35]
a UK 2000 PCPs (79: 40
intervention, 39
control)
Lansoprazole versus
omeprazole
PSR visits: PSRs instructed by
local health authority (one visit);
controls: normal detailing
Switch from omeprazole
to less costly lansoprazole
Dolovich [36]
a Canada 1999 PCPs and pediatric
specialists (641 in
intervention group
and 574 in control
group)
Antibiotics for otitis
media
PSR visits, PSRs trained in
evidence-based education by
academic department of a
university; Control group: no
detailing
Market share of antibiotics
for otitis media
Controlled
cohort studies
Andersen [37]
b Denmark
1999–2003
297 PCPs (26
intevention/271
controls)
Asthma medications Participation in a RCT funded
by a pharmaceutical company
Prescribing trial drug;
Adherence to prescribing
guidelines
Case-control
Studies
Spingarn [39] USu 1990 Hospital
residents (75)
Medications for Lyme
disease
Intervention: presentation by
academic who was also a
pharmaceutical executive;
Controls: did not attend
Appropriateness of
intention to prescribe for
mild versus severe Lyme
disease
Chren [38] US
1989–1990
Physicians (40
cases, 80 controls)
Addition to hospital
formulary
PSR visits; cases added to
formulary, controls did not
Addition of detailed
drug to hospital
formulary
Time series
analyses
(econometric)
Ching [78]
c Canada
1993–1999
Physician’s
prescribing
antihypertensives
in Canada
Antihypertensive
medications
(angiotensin
converting enzyme
inhibitors and
diuretics)
PSR visits (n minutes) Market share; Elasticity of
demand
Venkataraman
[40]
b
Not stated
2002–2003
Physicians
(2,774)
Statins, coagulation
drugs, erectile
dysfunction drugs,
gastrointestinal
drugs, placebo
PSR visits (total number);
attendance at pharmaceutical;
sponsored meetings; (total
number attended)
n prescriptions
Windmeijer [41]
c Netherlands
1995–1999
PCPs and
psychiatrists
d
11 therapeutic
markets (over 50%
of the Dutch drug
market)
PSR visits (expenditure); Journal
advertisements (expenditure);
Mail (expenditure)
n prescriptions; Cost of
prescriptions
Chintagunta [42]
c US, UK,
Germany,
France, Italy
1989–1999
Prescribers of
antidepressant
medications
Fluoxetine, sertraline,
paroxetine
PSR visits (expenditure) Market share (sales)
Narayanan [43]
e US
1993–2001
All prescribers of
antihistamines in
US
d
2nd generation
antihistamines:
loratidine cetirizine,
fexofenadine
PSR visits (total expenditure) New prescriptions per
month
Donohue [44]
c US
1997–2000
11,000 office and
hospital physicians
First prescriptions
of 6 antidepressants
Monthly spending on
PSR detailing
New prescriptions
Mizik [45]
b US 2004 Physicians (74,075) 3 unknown drugs PSR visits n new prescriptions for
the three study drugs
Manchanda [46]
b US
1999–2001
Physicians (1,000),
18.5% specialists
(for study drug),
60.1% PCPs, 21.4%
other specialists,
controls (1,000)
Drug unknown PSR visits Numbers of prescriptions
Manchanda and
Chintagunta [47]
b
US
1996–1998
Physicians
(1,000), 11%
specialists (for study
drug), 59% PCPs,
30% other specialists
Drug unknown PSR visits n prescriptions;
Prescriptions of specialists
versus primary care
physicians versus other
specialists; Prescriptions
by male and female
physicians
Berndt [48]
c US
1977–1993
All US physicians H2 antagonist
antiulcer drugs
(cimetidine, ranitidine,
famotidine, nizatidine)
PSR visits (min) Sales volume (units of
average daily dose) and
market share; Elasticity of
demand
Rosenthal [79]
c US
1996–1999
Large sample of
office and hospital
physicians
d
Medications
prescribed in
primary care
PSR visits (expenditure) Sales of detailed
medications per month
Pharma Information and Prescribing
PLoS Medicine | www.plosmedicine.org 8 October 2010 | Volume 7 | Issue 10 | e1000352Study Design
Study (First
Author Name)
Study Site,
Year Participants (n) Medication Intervention/Exposure Outcome Measure(s)
Azoulay [49]
c US
1977–1993
All prescribing
physicians
H2 antagonist
antiulcer drugs
(cimetidine, ranitidine,
famotidine, nizatidine)
PSR visits; Journal
advertisements
Market share for the four
H2 antagonists (patient
days of therapy)
Gonul [69]
c US
1989–1994
Physicians
d One medication for
a particular indication
‘‘relatively more
common among
the elderly’’
PSR visits (min) n prescriptions; Cost of
Prescriptions
Rizzo [50]
c US
1988–1993
All prescribers of
antihypertensives
in the US
d
Antihypertensive
medications
PSR visits (expenditure) Sales of detailed
medication; Price
elasticity; Quadratic term
for sales
Hurwitz [51]
c US
1978–1983
Specialists and
PCPs prescribing
promoted drugs
d
Brand and
generic drugs
Total promotional investment
in PSR visits, journal
advertising, direct mail
advertising
Market share held by
original brand; Market
share held by generic
competitors (measured in
n pills sold)
Mackowiak [52]
c US
1977–1981
Office based
physicians across
the US
d
Benzodiazepines
for anxiety; Diuretics
for hypertension
PSR visits (expenditure);
Journal advertisements
(expenditure)
Expenditure on
prescriptions; Market size
and market share
Leffler [53]
c US
1968–1977
Not stated
d 51 new products Total promotional outlay
(PSR visits, journal
advertising)
Market share 2 y after
market entry; Market share
in 1977 for drugs
introduced since 1968
expressed
Telser [54]
c US
1963–1972
All prescribing
physicians
d
Prescription
medications in: the
hospital market and
drugstore market
Promotional intensity: ratio
of total promotional outlays/
total sales (includes PSR visits,
journal advertising, direct mail)
Proportion of sales for
entrant drugs
Time series
analyses
(other)
Spurling [55] Australia
2004–2005
PCPs (7) Medications
prescribed in
primary care
PSR visits; Promotional items
in PCP surgeries
Generic prescribing (% of
total)
Stafford [56]
c US 1996–2002 Physicians (3,500) Alpha-blockers PSR visits (expenditure) Prescriptions
Charbit [34] France
1991–2001
Prescribing
physicians in
France
d
6 classes of
antihypertensive
medications
Journal advertising (n pages) Drug sales for each of the
six classes of
antihypertensive
medications
Auvray [57]
e France
1992–1998
PCPs, ear nose
throat surgeons,
chest physicians,
psychiatrists-1,600
Macrolide antibiotics
and psychoanaleptic
antidepressants
Total promotional investment n prescriptions
Cleary [26] US 1988 Physicians prescrib-
ing 3rd generation
cephalosporins
d
Ceftazidime,
cefriaxone,
cefotaxime
PSR visits New prescriptions; n doses
Soumerai [58]
e US
1974–1983
All propoxyphene
prescribers in USA
d
Propoxyphene PSR visits (to warn about
risks of propoxyphene)
Sales of propoxyphene;
No-refill rates of
prescriptions
Before–after
Studies
Hemminki [25]
e Estonia
2000
Gynecologists
and PCPs (342)
Hormone
replacement
therapy
Journal advertisements;
Pharmaceutical company-
sponsored medical education
Probability of detailed
drug being prescribed
Schwartz [27] US
1999–2000
Psychiatry
residents
d
Psychiatric
medications
PSR detailing (12 wk period
when residents were detailed
versus 12 wk with no detailing)
New prescriptions
Kazmierczak [59] US 1996 Physicians (60) Tramadol Drug company letter to
physicians warning about
tramadol seizure risk
Prescriptions for tramadol
in high risk patients
Orlowski [28] US 1992 Hospital
physicians (20)
Intravenous hospital
medications called A
(antibiotic) and B
(cardiovascular drug)
Attendance at pharmaceutical
sponsored meetings (all
expenses paid trips to
vacation site)
n prescriptions before and
after the sponsored
meetings
Bowman [60] US date
not stated
Physicians (374) Calcium channel
blockers and beta-
blockers
PSR sponsored continuing
medical education course
Self-reported new
prescriptions
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Cross-sectional
studies
Henderson [29] Australia
2003–2005
PCPs (1,336) 7 advertised
pharmaceutical
products
Advertising on clinical
software
n prescriptions
Kreyenbuhl [31] US
2003–2004
Psychiatrists
d Antipsychotic
medication
PSR visits; Attendance at
pharmaceutical sponsored
meetings
Use of ‘‘switch’’ or ‘‘add’’
strategies in treatment of
refractory schizophrenia
de Bakker [61] Netherlands
2001
PCPs (138) Medications
prescribed in
primary care
PSR visits; Reliance on
commercial sources of
information
n prescriptions
Steinman [62] US
1995–1990
Physicians (97) Gabapentin PSR visits Intention to prescribe
gabapentin
Greving [30] Netherlands
2003
PCPs (70) Angiotensin II
receptor blockers
PSR visits; Journal
advertisements; Attendance
at pharmaceutical
sponsored meetings
New prescriptions of this
drug
Canli [32] Turkey 2001 PCPs (316) Antibiotics for acute
tonsillopharyngitis
PSR visits Intention to prescribe
antibiotics
Verdoux [63] France 2004 PCPs (848) Antipsychotic
medication
PSR visits Initiation of antipsychotic
medication in a 1-mo period
Muijrers [64] Netherlands
2000–2001
PCPs (1,434) Medications
prescribed in
primary care
PSR visits Quality of prescribing
(determined by panel of
experts)
Huang [65] US
2001–2003
Resident physicians
d Antidepressants Sponsorship of resident
conferences
Prescription of
antidepressants from
sponsoring companies
Watkins [66] UK
1995–1996
PCPs (1,714) Medications
prescribed in
primary care
PSR visits (at least once per
week); Journal advertisements;
Reading written material from
pharmaceutical companies
Cost of prescriptions
Prosser [67] UK
1999–2000
PCPs (107) New medications
prescribed in
primary care
PSR visits; Journal
advertisements/mailings
(considered together)
New drug prescriptions
(high/medium/low
prescribers)
Caamano [68]
e Spain 1993 Physicians (234) All prescribing PSR visits n prescriptions ; Cost of
prescriptions
Mansfield [82] Australia
1999
PCPs (1,174) Medications used
in primary care
PSR visits (self-report);
Attendance at pharmaceutical
sponsored meetings (self-report)
Quality use of medicine
score
Jones [70] UK
1995–1997
PCPs
d Nine new drugs Journal advertisements Prescribing data for the
advertised drugs
Caudill [71] US 1996 PCPs (446) Medications for
acute bronchitis,
hypertension and
urinary tract infection
PSR visits (frequency of use) Cost of prescribing
Berings [72] Belgium date
not stated
PCPs (128) Benzodiazepines PSR visits (n visits in last 4 wk) Prescription of
benzodiazepines
Lurie [73] US
1987–1988
Hospital physicians
(240 faculty staff and
131 residents)
Hospital
medications
PSR visits (,5 min and .5 min) Change in prescribing
habit Addition to hospital
formulary
Healthcare
Communications
[80]
US
1987–1988
Physicians (1184) Newly promoted
medications
Journal advertisements
(awareness of)
Market share
Peay [33] Australia
1981
PCPs (74) and
specialists (50)
Temazepam PSR visits (contact versus no
contact); Direct mailing; Atten-
dance at PSR-sponsored function
Temazepam prescription
Blondeel [81] Belgium
1987
PCPs (358) Medications
prescribed by PCPs
PSR visits Response to 8 simulated
patients where prescribing
was not advisable. Quality
index compiled based on
GP medication choices by
expert panel (range 1–
100) Proneness to
prescribe (proxy for
prescribing frequency)
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with reduced price sensitivity for primary care providers and
psychiatrists in 11 therapeutic classes consisting of more than 50%
of the Dutch drug market [41]. Of three cross-sectional studies,
two detected an association between pharmaceutical sales
representative visits and higher prescribing costs [66,71], but one
did not detect an association [68]. One study also found that low
cost prescribers were more likely to have rarely or never read
promotional mail or journal advertisements from pharmaceutical
companies than high cost prescribers [66]. One time-series
analysis found that reduced exposure to pharmaceutical sales
representative visits and promotional material was associated with
an increase in generic prescribing [55]. A randomized controlled
trial of pharmaceutical sales representative visits in a noncom-
mercial partnership between a pharmaceutical company and a
local health authority measured physicians’ prescribing costs for
the target drug class and found no effect [35].
Discussion
Overview
We found that the reported relationship between exposure to
information provided directly by pharmaceutical companies and
the quality, frequency, and cost of prescribing varied from case to
case. However, with only one exception [39], the included studies
reported that exposure to information from pharmaceutical
companies was associated with either lower prescribing quality
or no association was detected. Similarly, exposure to information
from pharmaceutical companies was associated with either an
increase in prescribing frequency or no association was detected.
Three studies found that exposure was associated with increased
drug sales up to a point of diminishing returns beyond which more
promotion was increasingly less effective [46,50,69]. Finally, with
only one exception [69], exposure to information from pharma-
ceutical companies was associated with an increase in prescribing
costs or no association was detected.
This review has supported, updated, and extended the findings
of previous reviews regarding the effects of exposure to
information from pharmaceutical companies. 38 of the 58
included studies (66%) were not included in previous systematic
reviews on this topic [25,29–32,34,35,40–42,44,48,49,51–59,61–
68,70,72,75,76,78–82], including seven of the ten studies of
prescribing quality [37,58,59,61,64,81,82] and four of the seven
studies of prescribing costs [35,55,66,68].
Most of the included studies measured the frequency of
prescribing. Amongst these, the studies of informational exposure
where physicians are active participants, such as representatives’
visits, sponsored meetings, or sponsored trials, more consistently
found associations with higher prescribing frequency than studies
of more passive exposures, such as journal advertisements and
mailed information. Poor study quality precludes confident
conclusions about journal advertising. However, one higher
quality econometric analysis found that advertisements in journals
were associated with a more pronounced effect on market share
than positive scientific findings published in journals [49]. Also
there are claims in the marketing literature that the relatively low
cost of passive methods and their ability to synergistically increase
the effectiveness of active methods makes them cost effective
components of sales campaigns [84].
Limitations of Included Studies
All of the included studies had design limitations (Tables 1–5).
We found only two randomized controlled trials [35,36]. Both
lacked adequate reporting of allocation concealment and blinding.
These two trials did not examine standard promotional practice
but instead assessed novel partnerships of government or academia
with industry aiming for less expensive, higher quality prescribing.
On the basis of these two negative randomized controlled trials, it
seems unlikely that similar partnerships will have beneficial effects
on prescribing. No definite conclusions can be extrapolated from
these studies to standard promotional practice.
All other included studies were observational and thus able to
measure associations but not prove causation. There is a risk that
reported associations may be false positives, and that statistically
significant findings may not necessarily be clinically significant.
One example is the study by Mizik et al. that reports only a small
Study Design
Study (First
Author Name)
Study Site,
Year Participants (n) Medication Intervention/Exposure Outcome Measure(s)
Haayer [74] Netherlands
1979
PCPs (116) Medications that
would result from 8
case-histories devised
by a panel
PSR visits; Journal
advertisements;
Companies’ mailings
Prescribing rationality
based on a composite
scale (drug choice,
duration, dose and use of
combination products)
Walton [75] US 1976–77 PCPs (29%)
and specialists
(71%) (1,000 total)
186 different
medications
Journal advertisements Prescriptions of advertised
drugs (intention to
prescribe)
Dajda [76] UK 1975 PCPs in UK
d Branded advertised
drugs in the UK
Mailed advertisements
(number in 1 y)
n prescriptions
Becker [77] US 1970 PCPs (29), internists
(3). osteopathic
physicians (5)
Chloramphenicol,
equagesic, vitamin
B12, methylphenidate,
oral contraceptives
Use of journal
advertisements
PSR visits (frequency)
Proportion of
chloramphenicol scripts.
Physicians’ self-reported
prescribing behaviour.
aExperimental partnerships between pharmaceutical company and health authority or academic department.
bData from pharmaceutical company.
cInformation from a market research company.
dTotal number unknown.
eUsing national prescribing data.
PCP, primary care provider; RCT, randomized controlled trial.
doi:10.1371/journal.pmed.1000352.t006
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Exposure to Information
from Drug Company
Study (First
Author Name)
Result in Exposed Group Versus Controls (Where
Applicable)
Change in Prescribing
Quality Result
Effect of PSR visits de Bakker [61] Wider prescribing range was associated with more
visits from PSRs in the last 4 wk
Beta coefficient +0.18 (p,0.05)
a
Muijrers [64] More frequent visits from PSRs was associated with less
adherence to prescription guidelines
Multiple linear regression:
Beta 20.23 (95% CI 20.32 to
20.15) p,0.05
Mansfield [82] Frequency of visits from PSRs was not associated with
a difference in quality score
Pearson coefficient of 0.0363;
p=0.247
Blondeel [81] Based on responses to 8 case histories: Multivariate regression analysis:
First contact with a drug from the pharmaceutical
industry was not associated with quality index;
p.0.1
n PSRs received was associated with poorer quality index; p.0.05
Based on prescriptions for actual patients: First contact with
a drug from the pharmaceutical industry was associated
with reduced quality of prescribing;
p,0.01
n PSRs received was not associated with poorer quality index p.0.1
Becker [77] Fewer visits from PSRs/month were not associated with
a change in the appropriateness of prescribing
Gamma statistic; 0.04, not
statistically significant
Attendance at pharmaceutical
sponsored meeting
Mansfield [82] Attendance at pharmaceutical sponsored meetings was
associated with lower quality scores
Pearson correlation coefficient of
0.0635; p=0.043
Spingarn [39] Attendees at a sponsored talk about Lyme disease were less
likely to choose appropriate oral antibiotics for mild Lyme
disease than nonattendees
0% of attendees (n=22) chose
appropriate antibiotics compared
to 21% (n=53) of nonattendees;
Fisher exact test: p=0.027
For attendees and nonattendees of a sponsored talk about
Lyme disease there was no difference in choice of acceptable
treatment for Lyme disease with central nervous system signs
OR=3.2 (95% CI 0.8–19.2)
Attendees of a sponsored talk about Lyme disease were more
likely to appropriately choose the sponsoring company’s treat-
ment for Lyme disease complicated by 2nd degree heart block
OR=7.9 (95% CI 2.4–29.3)
Journal advertisements Becker [77] Infrequent use of journal ads as a source of prescribing
information by doctors was not associated with a change
in the appropriateness of prescribing
Gamma statistic 0.373, not
statistically significant
Total promotional invest-
ment/summated scores of
commercial information use/
general use of commercial
sources
de Bakker [61] There was a positive correlation for how frequently doctors
used the pharmaceutical industry as a source of information
and the range of drugs they prescribed
Beta coefficient +0.15 (p,0.05)
a
Haayer [74] Frequency of use of information from the pharmaceutical
industry was associated with less rational prescribing
Beta coefficient +0.134 ; p,0.001
Information delivered without
conventional promotion
Andersen [37] Participation in a randomized controlled trial was not
associated with a change in guideline adherence at 2 y
for trial sponsor’s medication
OR 1.00 (95% CI 0.84–1.19)
Kazmierczak [59] Mailed warning letters regarding tramadol for those with a
seizure risk were not associated with a change in prescription
rates for tramadol
9 (10%) prescriptions before and
7 (9%) after warning letters were
sent out no association detected
Soumerai [58] PSR visits: Propoxyphene use continued a preexisting decline
of about 8% a year during the time when warnings from the
manufacturing pharmaceutical company were conveyed by
PSRs after which time this decline halted, however a statistical
association was not shown. Refill rates and rates of overdose
did not change following the warnings
No association detected
Mailed Information: Propoxyphene use continued a preexisting
decline of about 8% a year during the time when warnings
from the manufacturing pharmaceutical company were
expressed by PSRs after which time this decline halted,
however a statistical association was not shown. Refill rates
and rates of overdose did not change following the warnings
No association detected
aAssumes a wide prescribing range is lower quality prescribing than a narrow prescribing range.
doi:10.1371/journal.pmed.1000352.t007
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Exposure to Information
from Drug Company
Study (First
Author Name) Results
Change in Prescribing Frequency
Results
Effect of PSR visits Ching [78] Higher levels of detailing for enalapril/hydrochlorothiazide
and lisinopril/hydrochlorothiazide was associated with
higher levels of demand (prescriptions)
Detailing elasticity 0.1–0.27 (p,0.05)
Kreyenbuhl [31] Meeting PSRs .4 times in the preceding month was not
associated with the ‘‘add’’ rather than ‘‘switch’’ strategy
for antipsychotic medication prescribing
OR 1.22 (95% CI 0.68–2.20)
Steinman [8] PSR visits of #5 min versus .5 min were not associated
with intention to prescribe
No association detected
PSR visits to doctors in a small group were associated with
increase in more frequent intention to prescribe
a
OR 12.9 (95% CI 1.2–138.8)
b
PSR visits were associated with increased gabapentin
prescribing if physician’s previous gabapentin prescribing
was nil
a
OR 15.1 (95% CI 3.9–58.2)
b reference
group - medium prescribers of
gabapentin
PSR visits were associated with increased gabapentin
prescribing if physician’s previous gabapentin prescribing
was low
a
OR 8.6 (95% CI 2.4–31.4)
b reference
group, medium prescribers of
gabapentin
Venkataraman [40] PSR visits were associated with increased n prescriptions Beta coefficient: +0.944 (significant
with a 95% CI)
Canli [32] PSR visits were associated with increased antibiotic prescribing
a p=0.0001*
Chintagunta [42] Higher levels of detailing were associated with higher
market share for that brand in the three of the countries
studied and no significant difference in two others
Detailing related change in market
share; US; beta coefficient +0.06; t
statistic 3 (p,0.05); Germany; beta
coefficient +0.73; t statistic 3.6
(p,0.05); France; beta coefficient
+4.17; t statistic 7.87 (p,0.05); Italy;
beta coefficient +0.24; t statistic 0.96
(p.0.05); UK; beta coefficient +0.29; t
statistic 1.61 (p.0.05)
Narayanan [43] PSR visits were associated with an increase in market share 1% increase in expenditure on
detailing was associated with
increases in market shares for
promoted drugs ranging from 0.11%
to 0.14% (p,0.05)
Verdoux [63] PSR visits were associated with general practitioners
initiating a newer antipsychotic medication
OR 2.80 (95% CI 2.09–3.76); p=0.0001
Mizik [45] PSR visits were associated with increased prescribing
of Drugs A, B. and C
Drug A: 1 PSR visit generates 1.56 new
prescriptions (95% CI 0.8–2.23) or 0.64
visits to induce one prescription
Drug B: 1 PSR visit generates 0.32 new
prescriptions (95% CI 0.22–0.43) or
3.11 visits to induce one prescription
Drug C: 1 PSR visit generates 0.153
new prescriptions (95% CI 0.11–0.2) or
6.54 visits to induce one prescription
Donohue [44] Expenditure on PSR visits is associated with higher
probability that the detailed antidepressant is prescribed
Beta coefficient +0.703 (p,0.001)
Stafford [56] Decreasing promotional expenditure was associated
with a decrease in prescribing for alpha blockers
c
Decreased with decreased promotion
Manchanda [46] PSR visits were associated with more new prescriptions 1.8 detailing visits results in 5 new
prescriptions (average result)
b
Manchanda and
Chintagunta [47]
PSR visits were not associated with a significant
change in mean prescriptions
Beta coefficient +0.83 detailing t
statistic 0.675 (p.0.05)
More frequent PSR visits were associated with diminishing
increases in prescribing
Quadratic term for PSR visits: 20.49; t
statistic 20.49 (p.0.05)
Berndt [48] PSR detailing were associated with increased cumulative
days of therapy
Beta coefficient +0.7414; t statistic
43.12 (p,0.01)
Rosenthal [79] PSR visits were associated with increased frequency of
prescription
Beta coefficient +0.017; t statistic 4.25
(p,0.05)
Prosser [67] PSR visits were more likely to be cited as a prescribing
influence by high prescribers than by low prescribers
OR 7.32 (95% 1.64–32.61); Fisher exact
test; p=0.002
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Azoulay [49] PSR detailing is associated with diffusion of product
information and performance on the product market with
marketing activities having a more pronounced effect than
scientific information in the form of clinical trial reports
c
Beta coefficient +0.654; t statistic
10.17 (p,0.05)
Gonul [69] PSR visits in minutes were a positive predictor of
medication prescription
Beta coefficient +0.1085; t statistic
5.32 (p,0.001)
Caamano [68] PSR visits were not associated with the n prescriptions Adjusted regression coefficient
20.490.001; p=0.998
Schwartz [27] PSR visits to residents were associated with increased
initiation of prescriptions for 12 drugs
a
p,0.05 for all*
PSR visits were not associated with increased prescription
of one medication however for this medication unlike the
others there had been more PSR visits in the control group
No association detected (p.0.05)*
Rizzo [50] PSR visits were associated with increased prescription sales Beta coefficient +0.28; t statistic 4.19
(p,0.01)
PSR visits may result in diminishing returns given the quadra-
tic beta coefficient is statistically significant and negative
Quadratic sales coefficient for PSR
visits: 20.490.01 (p.0.05)
Chren [38] PSR meetings were associated with a formulary request Multivariate result: OR=3.4 (95% CI
1.8–6.6); p,0.001
Berings [72] PSR visits were not significantly associated with
benzodiazepine prescribing
a
Linear regression analysis: beta 0.16
(p=0.05 to 0.1)
Cleary [26] PSR visits were associated with an increase in prescribing
of promoted medications; prescribing of them decreased
when they were not promoted
Ceftriaxone 24.2% and 27.8% increase
in promoted periods; p,0.05
Cefotaxime 14.6% and 26.2% increase
in promoted periods; p,0.05
Ceftazidime (promoted in period I but
not promoted in period II): 27.7%
decrease when not promoted in
period II (p,0.05) and 10% increase in
period III after being promoted again;
p,0.05
Lurie [73] PSR visits for faculty staff for less than 5 min were
associated with more prescribing
Logistic regression coefficient 0.016;
p=0.03
PSR visits for faculty staff for more than 5 min were not
associated with a change in prescribing
p.0.10 (coefficient not presented
where result not significant)
PSR visits for faculty staff for less than 5 min were not
associated with an addition to the hospital formulary
Logistic regression coefficient 0.014;
p=0.06
PSR visits for faculty staff for more than 5 min were not
associated with an addition to the hospital formulary
p.0.10 (coefficient not presented
where result not significant)
PSR visits for residents for less than 5 min were associated
with more prescribing
Logistic regression coefficient 0.049;
p=0.003
PSR visits for residents for more than 5 min were not
associated with a change in prescribing
p.0.10 (coefficient not presented
where result not significant)
PSR visits for residents for less than 5 min were not
associated with an addition to the hospital formulary
p.0.10 (coefficient not presented
where result not significant)
PSR visits for residents for more than 5 min were not
associated with an addition to the hospital formulary
p.0.10 (coefficient not presented
where result not significant)
Peay [33] PSR visits were associated with temazepam prescription Multivariate regression: 20.35
(p,0.002)
Blondeel [81] Based on responses to 8 case-histories: Multivariate regression:
First contact with a drug from the pharmaceutical
industry was not associated with proneness to prescribe
p=0.05–0.1
Number of PSRs received was not associated with
proneness to prescribe
p.0.1
Based on prescriptions for actual patients:
First contact with a drug from the pharmaceutical
industry was not associated with proneness to prescribe
p.0.1
Number of PSRs received was associated with proneness
to prescribe
p,0.05
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Mackowiak [52] PSR visit expenditure was not associated with a change
market size nor market share for benzodiazepines or diuretics
No association detected
Becker [77] PSR visits per month were not associated with
chloramphenicol prescribing
Gamma statistic 0.236; not significant
Journal advertisements Hemminki [25] Journal advertisements were associated with a trend for
increased hormone replacement therapy (HRT) prescribing
in Estonia
Increased prescriptions
Charbit [34] Journal advertising was associated with increased
prescriptions of ARA. When journal advertisements for
ACE inhibitors and CCB decreased, their market share
also decreased
10.5% decrease in mean annual
advertising of ACE inhibitors
associated with 19.3% decrease in
market share 11% decrease in mean
annual advertising for CCBs associated
with 19.3% decrease in market share.
20.5% increase in mean annual
advertising rate for ARAs associated
with 22.9% increase in market share
Prosser [67] Journal advertisements were no more likely to be cited
as a prescribing influence by high prescribers than by low
prescribers
9% high prescribers versus 0% of low
prescribers; Fisher exact test; p=0.18
Azoulay [49] Journal advertisements were associated with diffusion of
product information and performance on the product market
with marketing activities having a more pronounced effect
than scientific information in the form of clinical trial reports
c
Beta coefficient +0.112; t statistic
4.753 (p,0.05)
Jones [70] Journal advertisements were not associated with PCP
prescribing
No association detected
Healthcare
Communications
[80]
Journal advertisement recognition was associated with
increased market share for the advertised medication
14.5% difference in market share
between those physicians not
recognising advertisements (19.6%)
and those associating the
advertisement message with the
product (34.1%)
Walton [75] Journal advertisement recognition was associated with
medication prescription
OR 1.68 (95% CI 1.21–2.35)
b
Becker [77] Infrequent use of journal advertisement use was not
associated with chloramphenicol prescribing
Gamma statistic 20.186 not
statistically significant
Infrequent use of journal advertisements to learn about the
usefulness of new medications was associated with reduced
chloramphicol prescribing
a
Gamma statistic +0.51; p,0.05
Attendance at pharmaceutical
company-sponsored meeting
Kreyenbuhl [31] Attendance at pharmaceutical sponsored CME meetings more
than once in the preceding month was associated with the
‘‘add’’ rather than ‘‘switch’’ strategy for antipsychotic
medication prescribing
a
OR 2.32 (95% CI 1.29–4.18); p=0.005*
Venkataraman [40] Attendance at pharmaceutical sponsored meetings was not
significantly associated with prescriptions for 7 out of 12
brands
Beta coefficient 20.659 (significant
with a 90% CI)
Narayanan [43] Attendance at pharmaceutical company-sponsored meetings
was associated with an increase in promoted medication
market share
A 1% increase in expenditure on
‘‘other marketing activities’’ (including
meetings) was associated with
increases in market shares for
promoted drugs ranging from 0.02%
to 0.04% (p,0.05)
Huang [65] Attendance at pharmaceutical sponsored conferences was
associated with more prescriptions of the corresponding
sponsored antidepressant
a
Pearson correlation coefficient; 2001–
2002: 0.87; p,0.01, 2002–2003: 0.73;
p,0.01
Spingarn [39] Attendance at a pharmaceutical sponsored meeting was not
associated with the intention to prescribe the promoted
medication where it was indicated
OR 2.51 (95% CI 0.91–6.95)
Orlowski [28] Attendance at pharmaceutical sponsored meeting was
associated with more prescriptions of medications being
discussed
Drug A: 81 (644) prescriptions before,
272 (6117) prescriptions after;
p,0.001 (Wilcoxon rank sum)
Drug B: 34 (630) prescriptions before,
87 (624) prescriptions after; p,0.001
(Wilcoxon rank sum)
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Bowman [60] Attendance at pharmaceutical sponsored courses was
associated with more prescriptions of medication made
by sponsoring company
Before and 6 mo after 3 sponsored
course involving sponsoring
company’s drugs:
Course I: Nifedipine, increase in
prescriptions 5.6%; p,0.05*
Course II: Metoprolol, increase in
prescriptions 12.4%; p,0.05*
Course III: Diltiazem, increase in
prescriptions 18.7%; p,0.05*
Peay [33] Attendance at pharmaceutical sponsored meeting was
not associated with prescription of temazepam
No association detected
Mailed information from
pharmaceutical companies
Prosser [67] Mailed information was no more likely to be cited as an
influence by high prescribers than low prescribers
a
9% for high prescribers, 0% for low
prescribers; Fisher exact test; p=0.18
Peay [33] Mailed information was not associated with a change in
temazepam prescribing frequency
No association detected
Dajda [76] Mailed advertisements to general practitioners was
associated with an increase in prescriptions
Correlation coefficient 0.08
Advertising on clinical software Henderson [29] Advertisements on clinical software were not associated
with a difference in prescribing for all advertised
medications combined
Adjusted OR 0.96 (95% CI 0.87–1.06);
p=0.42
Total promotional investment/
summated scores of commercial
information use/general use of
commercial sources
Greving [30] Commercial information sources of information were
associated with an increase in rates of prescribing of
angiotensin receptor blocking medications
OR 2.0 (95% CI 1.5–2.6)
Commercial information sources of information were not
associated with an increase in the n doctors prescribing
angiotensin receptor blocking medications
OR 12.8 (95% CI 0.20–816.58)
Windmeijer [41] Expenditure on pharmaceutical promotion was associated
with more prescribing
Beta coefficient +0.0137; t statistic
2.98 (p,0.01)
Auvray [57] Total promotional investment was associated with an
increase in the n prescriptions
No statistical measures presented
Peay [33] Commercial information sources were associated with
a preference for temazepam prescribing
a
p,0.036 (t test)
Commercial information sources were associated with
earlier temazepam prescribing
a
p,0.045 (t test)
Hurwitz [51] Promotion of the branded leading drug was associated with
increased market share especially for acute or sporadic conditions
Beta coefficient +0.295; t statistic 4.34
(p,0.01)
Promotion of ‘‘following generic drugs’’ was associated with
reduced the market share for the leading drug
Beta coefficient 20.150; t statistic 2.14
(p,0.05)
Mackowiak [52] Expenditure on PSRs and journal advertisements was not
associated with a change in market size nor market share for
benzodiazepines or diuretics
No association detected
Leffler [53] The promotional intensity for new products was not
associated with increased market share for the entrant
product 2 y post introduction
Beta coefficient +0.88; t statistic 1.89,
p.0.05
The promotional intensity for new products introduced
over a 9-y period was associated with increased market
share for the entrant products
Beta coefficient +1.25; t statistic 2.35,
p,0.05
Telser [54] Overall promotional intensity was associated with the
market share of entrant drugs in the hospital and drug
store market in the period 1964–1968
Drug store: beta coefficient +1.28; t
statistic +2.20 (p,0.05)
Hospital: beta coefficient +1.45; t
statistic +2.61 (p,0.05)
Overall promotional intensity was not associated with
the market share of entrant drugs in the hospital and
drug market in the period 1968–1972
Drug store: beta coefficient +1.19; t
statistic +0.60 (p.0.05)
Hospital: beta coefficient +0.608; t
statistic +1.20 (p.0.05)
Information delivered without
conventional promotion
Andersen [37] Participation in pharmaceutical funded research was associated
with increase in the sponsoring company’s share of asthma drug
in practices conducting the trial compared to control practices
6.7% increase (95% CI 3.0%–11.7%)
b
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sales representatives [45]. Associations may also arise from
confounding, bias, or chance. False negatives or inaccurate
estimation of effect sizes may result from small sample sizes,
measurement errors, overly complex models, or ‘‘contamination’’
when prescribers who are thought to be unexposed are actually
influenced by other methods. For example in a study of
promotional meetings, nonattenders may be influenced by sales
representatives thus reducing the difference from attenders in their
prescribing. Another possible source of contamination is indirect
influence by colleagues who have been influenced directly.
To the extent that the measured associations are real, causality
may be bidirectional. The influence of information from
pharmaceutical companies on prescribing is a likely explanation
for the associations given that the major purpose of pharmaceu-
tical promotion is to influence prescribing [3]. However, it is also
possible that physicians who prescribe larger quantities, more
expensively or less appropriately may allow themselves to be
exposed to, or attract, more promotional information.
Some studies found no association between exposure to
information from pharmaceutical companies and prescribing
outcomes or small effect sizes that seem unlikely to be clinically
significant. Some of these may be false negatives or underestima-
tions caused by study flaws, but it is likely that information from
companies sometimes has little or no effect, especially when the
information is not designed to increase sales, e.g., letters warning
about safety problems. Most of the studies included in this review
examined single components of promotional campaigns that may
have little or no effect alone but have a synergistic effect in
combination with other components. Promotion may be less
effective if it is used beyond the point of diminishing returns or is
up against similarly effective promotion for another similar product.
Exposure to Information
from Drug Company
Study (First
Author Name) Results
Change in Prescribing Frequency
Results
Freemantle [35] PSR visits were not associated with an increase in the
prescription of the detailed medication
OR=1.04 (95% CI 0.83–1.31); p=0.73
Dolovich [36] PSR visits were not associated with a change in the market
share of amoxicillin
Intervention group: +0.63% market
share, control group: 20.72% market
share; p=0.15
Kazmierczak [59] Mailed warning letters regarding tramadol for those with a
seizure risk were not associated with a change in prescription
rates for tramadol
a
Before mailing: 10% prescribing rate,
after mailing 9% prescribing rate.
Soumerai [58] PSR visits: Propoxyphene use continued a preexisting decline
of about 8% a year during the time when warnings from the
manufacturing pharmaceutical company were expressed by
PSRs after which time this decline halted, however a statistical
association was not shown. Refill rates and rates of overdose
did not change following the warnings
a
No association detected
Mailed information: Propoxyphene use continued a
preexisting decline of about 8% a year during the time when
warnings from the manufacturing pharmaceutical company
were expressed by PSRs after which time this decline halted,
however a statistical association was not shown. Refill rates
and rates of overdose did not change following the
No association detected
aStudy authors reported that exposure to information from drug companies was associated with decreased quality of prescribing.
bReported by study authors as statistically significant.
cStudy authors reported that exposure to information from drug companies was associated with increased quality of prescribing.
*Chi-squared statistic.
ACE, angiotensin converting enzyme; ARA, angiotensin receptor antagonist; CCB, calcium channel blocker; CME, continuing medical education.
doi:10.1371/journal.pmed.1000352.t008
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Figure 2. Forest plot displaying the effect of promotional information on physicians’ prescribing of the promoted medication.
doi:10.1371/journal.pmed.1000352.g002
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reasons why the studies could be biased overall in either direction.
Authors may have produced results consistent with their
ideological bias. Also reciprocal obligation to funders who
preferred certain results may have lead to bias with or without
conscious awareness. Publication and outcome reporting bias may
have led to underrepresentation of negative, positive, uninterest-
ing, or unwanted findings.
Strengths and Weaknesses
The strengths of this review include use of a comprehensive
search strategy over multiple databases without any language
exclusions. We consulted widely with experts in the field and we
used validated instruments to assess quality of the studies.
However, only one of the included studies was conducted in a
low-income economy, as defined by the World Bank, so the effects
of promotion there are less certain [33]. This study found a
positive association between pharmaceutical promotion and
prescribing frequency. Promotion may be more influential in
these countries given the relative paucity of independent sources of
information [85,86].
Our efforts to access data that was not in the databases we
searched had mixed results. Messages on e-mail discussion groups
and contact with experts yielded five additional studies subsequent
to the initial search [34,43,80–82] whose results were consistent
with the entire review. By contrast, pharmaceutical companies did
not provide us with any information that was not already in the
public domain. However five studies included in this review
analyzed confidential data from pharmaceutical companies and
their results were also consistent with the review as a whole
[33,35,37,40,46].
Given the wide range of knowledge and experience among the
sources that we consulted and the expertise in our group, we are
confident that we exhausted all reasonable avenues in our attempt
to obtain additional literature.
Data Interpretation
Of the 58 studies included in this review, 38 studies reported a
single unit of analysis with 25 (66%) finding significant
associations between exposure to information from pharmaceu-
tical companies and the quality, frequency, and cost of pre-
scribing and eight (21%) finding no associations. The remaining
five (13%) had multiple measures and found significant associa-
tions on some measures but not on others. The 20 studies with
more than one unit of analysis reported 49 units of analysis of
which 21 (43%) found significant associations, 24 (49%) found no
associations, and four (8%) found mixed results. The difference
between the results of the single versus multiple unit of analysis
studies is significant (p,0.05 Freeman-Halton extension of the
Fisher exact test). This difference may have been caused by
publication bias against publication of single unit of analysis
studies when no association was found. We believe the pattern of
results suggests that there was little or no reporting bias for the
multiple unit of analysis studies. Because the multiple unit of
analysis studies found no association more often than the single
unit of analysis studies, multiple mentions of the former studies in
our narrative synthesis will not exaggerate the frequency of
findings of significant associations.
Table 9. Relationship between exposure to information from drug companies and prescribing costs (by year of publication and
then study design/size).
Exposure to Information from
Drug Company
Study (First
Author Name) Results Change in Prescribing Costs
Effect of PSR visits Watkins [66] High cost prescribers were more likely to see PSRs
at least once a week than low cost prescribers
OR 3.11 (95% CI 2.48–3.89); p,0.01
a
Caamano [68] There was no association between PSR visits and
the cost of prescriptions
Adjusted regression coefficient: 21.0;
p=0.962
Gonul [69] PSR visits were associated with increased physicians’
price sensitivity
Maximum likelihood estimate, 0.0012;
t statistic 3 (p,0.001)
Rizzo [50] PSR visits were associated with reduced price elasticity
for the promoted drug
Sales estimate +0.14; t statistic 2.97
(p,0.01)
Caudill [71] Frequency of PSR visits was associated with higher
prescribing costs
Multivariate regression beta +0.155;
p=0.01
Journal advertisements Watkins [66] High cost prescribers were less likely to ‘‘rarely or never’’
read journal advertisements than low cost prescribers
OR 0.79 (95% CI 0.64–0.98); p=0.02
a
Mailed information from
pharmaceutical companies
High cost prescribers were less likely to ‘‘rarely or never’’
read mailed information than low cost prescribers
OR 0.49 (95% CI 0.38–0.64); p,0.01
a
Total promotional investment/
summated scores of commercial
information use/general use of
commercial sources
Spurling [55] Reduced n PSR visits and volume of promotional
material were associated with an increased generic
prescribing at 3 and 9 mo
3 mo: OR 2.28 (95% CI 1.31–3.86);
p=0.0027
a
9 mo: OR 2.07 (95% CI 1.13–3.82);
p=0.016
a
Windmeijer [41] Promotional outlay (PSR visits, journal advertisements,
direct mail) was associated with reduced price elasticity
for promoted drugs
ln regression coefficient 20.0102 (se
0.0055) p,0.05
Information delivered without
conventional promotion
Freemantle [35] There was no significant difference in costs between
the group that was detailed by PSRs instructed by a
local health authority and the control group
Mean difference: £122.32 (95% CI
2£94.91 to £342.91)
aChi-squared statistic.
doi:10.1371/journal.pmed.1000352.t009
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many studies included in the narrative synthesis could not be
included in the meta-analysis. Where a sufficient number of studies
could be combined, there was significant heterogeneity. The
summary result has not been presented because it is unlikely to
accurately reflect the true effect size of most promotional
campaigns for two main reasons. First, effect sizes varied widely
so it is likely that promotional campaigns often have effect sizes far
from average. Second, single promotional techniques are likely to
be less effective individually than campaigns employing multiple
promotional methods.
A sensitivity analysis found the difference between passive and
active promotion is one possible cause of heterogeneity. Other
possible explanations for variation in the effectiveness of
promotion include variation from campaign to campaign in the
relative benefits of the drug being promoted, the promoter’s skills
and budget, and the target group’s level of resistance to
promotion.
Conclusions
The limitations of studies reported in the literature mentioned
above mean that we are unable to reach any definitive conclusions
about the degree to which information from pharmaceutical
companies increases, decreases, or has no effect on the frequency,
cost, or quality of prescribing. In theory, advertising may be
beneficial in several ways: by distributing information and thus
improving the quality of prescribing [20,78], by reducing costs
through increasing price-elasticity [69], by increasing prescribing
of drugs that provide better health outcomes, or by improving the
cost-effective use of healthcare resources. Because of the
limitations of both the included studies and this review we have
not disproved those theories but we have found little evidence to
support them and have found some evidence of increased costs
and decreased quality of prescribing. Any conclusions about harm
or benefit for patients are speculative because none of the studies
that we found examined clinical outcomes. One clear conclusion
from this review is that we did not find evidence of net
improvements in prescribing associated with exposure to infor-
mation from pharmaceutical companies.
Some argue that prescribers have an ethical duty to avoid
exposure to pharmaceutical promotion [13,87–89]. Even ineffec-
tive promotional information may be harmful if it wastes
prescribers’ time or if the money spent on promotion increases
the cost of medicines [90]; this is of concern given the large
expenditure involved [1,2]. In the absence of evidence of net
improvement in prescribing from exposure to promotional
information, we recommend that practitioners follow the precau-
tionary principle and thus avoid exposure to information from
pharmaceutical companies unless evidence of net benefit emerges.
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Background. A prescription drug is a medication that can
be supplied only with a written instruction (‘‘prescription’’)
from a physician or other licensed healthcare professional. In
2009, 3.9 billion drug prescriptions were dispensed in the US
alone and US pharmaceutical companies made US$300
billion in sales revenue. Every year, a large proportion of
this revenue is spent on drug promotion. In 2004, for
example, a quarter of US drug revenue was spent on
pharmaceutical promotion. The pharmaceutical industry
claims that drug promotion—visits from pharmaceutical
sales representatives, advertisements in journals and
prescribing software, sponsorship of meetings, mailed
information—helps to inform and educate healthcare
professionals about the risks and benefits of their products
and thereby ensures that patients receive the best possible
care. Physicians, however, hold a wide range of views about
pharmaceutical promotion. Some see it as a useful and
convenient source of information. Others deny that they are
influenced by pharmaceutical company promotion but claim
that it influences other physicians. Meanwhile, several
professional organizations have called for tighter control of
promotional activities because of fears that pharmaceutical
promotion might encourage physicians to prescribe
inappropriate or needlessly expensive drugs.
Why Was This Study Done? But is there any evidence that
pharmaceutical promotion adversely influences prescribing?
Reviews of the research literature undertaken in 2000 and
2005 provide some evidence that drug promotion influences
prescribing behavior. However, these reviews only partly
assessed the relationship between information from
pharmaceutical companies and prescribing costs and
quality and are now out of date. In this study, therefore,
the researchers undertake a systematic review (a study that
uses predefined criteria to identify all the research on a given
topic) to reexamine the relationship between exposure to
information from pharmaceutical companies and the quality,
quantity, and cost of physicians’ prescribing.
What Did the Researchers Do and Find? The researchers
searched the literature for studies of licensed physicians who
were exposed to promotional and other information from
pharmaceutical companies. They identified 58 studies that
included a measure of exposure to any type of information
directly provided by pharmaceutical companies and a
measure of physicians’ prescribing behavior. They then
undertook a ‘‘narrative synthesis,’’ a descriptive analysis of
the data in these studies. Ten of the studies, they report,
examined the relationship between exposure to phar-
maceutical company information and prescribing quality
(as judged, for example, by physician drug choices in
response to clinical vignettes). All but one of these studies
suggested that exposure to drug company information was
associated with lower prescribing quality or no association
was detected. In the 51 studies that examined the relation-
ship between exposure to drug company information and
prescribing frequency, exposure to information was
associated with more frequent prescribing or no
association was detected. Thus, for example, 17 out of 29
studies of the effect of pharmaceutical sales representatives’
visits found an association between visits and increased
prescribing; none found an association with less frequent
prescribing. Finally, eight studies examined the relationship
between exposure to pharmaceutical company information
and prescribing costs. With one exception, these studies
indicated that exposure to information was associated with a
higher cost of prescribing or no association was detected. So,
for example, one study found that physicians with low
prescribing costs were more likely to have rarely or never
read promotional mail or journal advertisements from
pharmaceutical companies than physicians with high
prescribing costs.
What Do These Findings Mean? With rare exceptions,
these findings suggest that exposure to pharmaceutical
company information is associated with either no effect on
physicians’ prescribing behavior or with adverse affects
(reduced quality, increased frequency, or increased costs).
Because most of the studies included in the review were
observational studies—the physicians in the studies were
not randomly selected to receive or not receive drug
company information—it is not possible to conclude that
exposure to information actually causes any changes in
physician behavior. Furthermore, although these findings
provide no evidence for any net improvement in prescribing
after exposure to pharmaceutical company information, the
researchers note that it would be wrong to conclude that
improvements do not sometimes happen. The findings
support the case for reforms to reduce negative influence to
prescribing from pharmaceutical promotion.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000352.
N Wikipedia has pages on prescription drugs and on
pharmaceutical marketing (note that Wikipedia is a free
online encyclopedia that anyone can edit; available in
several languages)
N The UK General Medical Council provides guidelines on
good practice in prescribing medicines
N The US Food and Drug Administration provides informa-
tion on prescription drugs and on its Bad Ad Program
N Healthy Skepticism is an international nonprofit member-
ship association that aims to improve health by reducing
harm from misleading health information
N The Drug Promotion Database was developed by the
World Health Organization Department of Essential Drugs
& Medicines Policy and Health Action International Europe
to address unethical and inappropriate drug promotion
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